Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2024 Jun 12

PMID 38867099

Authors

Hoda Pourhassan

Lindsey Murphy

Ibrahim Aldoss

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Glucocorticoids are a mainstay in acute lymphoblastic leukemia treatment and lack of early response is predictive for overall disease prognosis. Given the vital position of glucocorticoids and well known long and short-term side effects associated with differing glucocorticoids, we aim to highlight the wide breadth of historical and more contemporary data to describe the current landscape of glucocorticoid use in this arena.

Recent Findings: Emerging studies aim to overcome issues such as steroid resistance and to optimize the antileukemic effects of glucocorticoids while aiming to mitigate the risks and side effects associated with their exposure. Glucocorticoids have and likely always will be a fundamental component of acute lymphoblastic leukemia treatment and understanding how to navigate short- and long-term effects and how to optimize regimens is at the heart of continued treatment success.

Citing Articles

Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?.

Jalali A, Mitchell K, Pompoco C, Poludasu S, Tran S, Ramana K Int J Mol Sci. 2025; 25(24.

PMID: 39769450 PMC: 11728390. DOI: 10.3390/ijms252413689.

References

Burger B, Beier R, Zimmermann M, Beck J, Reiter A, Schrappe M . Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer. 2004; 44(3):220-5. DOI: 10.1002/pbc.20244. View

Borin C, Pieters T, Serafin V, Ntziachristos P . Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia. Hemasphere. 2023; 7(7):e916. PMC: 10289758. DOI: 10.1097/HS9.0000000000000916. View

Orgel E, Mueske N, Wren T, Gilsanz V, Butturini A, Freyer D . Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016; 85:131-7. PMC: 4795805. DOI: 10.1016/j.bone.2016.01.027. View

Lowas S, Marks D, Malempati S . Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 52(7):814-8. DOI: 10.1002/pbc.21980. View

Hohtari H, Kankainen M, Adnan-Awad S, Yadav B, Potdar S, Ianevski A . Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. Hemasphere. 2022; 6(3):e701. PMC: 8878725. DOI: 10.1097/HS9.0000000000000701. View

Hurwitz C, Silverman L, Schorin M, Clavell L, Dalton V, Glick K . Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000; 88(8):1964-9. View

Hunger S . Glucocorticoid selection for pediatric ALL. Blood. 2016; 127(17):2049-51. DOI: 10.1182/blood-2016-02-701664. View

Kaspers G, Veerman A, Popp-Snijders C, Lomecky M, van Zantwijk C, Swinkels L . Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996; 27(2):114-21. DOI: 10.1002/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I. View

Cain D, Cidlowski J . Specificity and sensitivity of glucocorticoid signaling in health and disease. Best Pract Res Clin Endocrinol Metab. 2015; 29(4):545-56. PMC: 4549805. DOI: 10.1016/j.beem.2015.04.007. View

10.

Lu N, Cidlowski J . Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005; 18(3):331-42. DOI: 10.1016/j.molcel.2005.03.025. View

11.

Roderick J, Gallagher K, Murphy L, OConnor K, Tang K, Zhang B . Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. Blood. 2021; 137(4):500-512. PMC: 7845005. DOI: 10.1182/blood.2020005712. View

12.

Gao J, Liu W . Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018; 22(22):7858-7866. DOI: 10.26355/eurrev_201811_16411. View

13.

Popoviciu M, Paduraru L, Yahya G, Metwally K, Cavalu S . Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023; 24(13). PMC: 10341852. DOI: 10.3390/ijms241310449. View

14.

Garmey E, Liu Q, Sklar C, Meacham L, Mertens A, Stovall M . Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008; 26(28):4639-45. PMC: 2653124. DOI: 10.1200/JCO.2008.16.3527. View

15.

Meyer L, Delgado-Martin C, Sharp P, Huang B, McMinn D, Vincent T . Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2022; 198(1):137-141. PMC: 9322670. DOI: 10.1111/bjh.18181. View

16.

Inaba H, Pui C . Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11):1096-106. PMC: 3309707. DOI: 10.1016/S1470-2045(10)70114-5. View

17.

Paugh S, Bonten E, Savic D, Ramsey L, Thierfelder W, Gurung P . NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015; 47(6):607-14. PMC: 4449308. DOI: 10.1038/ng.3283. View

18.

Gregoriou K, Craigie I, Gibson B, Mason A, Shaikh M . Risk factors and management of corticosteroid-induced hyperglycaemia in paediatric acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2019; 67(2):e28085. DOI: 10.1002/pbc.28085. View

19.

Dare J, Moppett J, Shield J, Hunt L, Stevens M . The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2013; 60(12):E157-9. DOI: 10.1002/pbc.24689. View

20.

Rangel-Patino J, Lee-Tsai Y, Urbalejo-Ceniceros V, Luna-Perez M, Espinosa-Bautista K, Amador L . A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023; 7(18):5202-5209. PMC: 10500455. DOI: 10.1182/bloodadvances.2023009754. View